| Year |
Citation |
Score |
| 2018 |
Rouaud F, Hamouda-Tekaya N, Cerezo M, Abbe P, Zangari J, Hofman V, Ohanna M, Mograbi B, El-Hachem N, Benfodda Z, Lebeau A, Tulic MK, Hofman P, Bertolotto C, Passeron T, et al. E2F1 inhibition mediates cell death of metastatic melanoma. Cell Death & Disease. 9: 527. PMID 29743521 DOI: 10.1038/s41419-018-0566-1 |
0.326 |
|
| 2018 |
Didier R, Mallavialle A, Ben Jouira R, Domdom MA, Tichet M, Auberger P, Luciano F, Ohanna M, Tartare-Deckert S, Deckert M. Targeting the proteasome-associated deubiquitinating enzyme USP14 impairs melanoma cell survival and overcomes resistance to MAPK-targeting therapies. Molecular Cancer Therapeutics. PMID 29703842 DOI: 10.1158/1535-7163.MCT-17-0919 |
0.337 |
|
| 2018 |
Ohanna M, Cerezo M, Nottet N, Bille K, Didier R, Beranger G, Mograbi B, Rocchi S, Yvan-Charvet L, Ballotti R, Bertolotto C. Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotype. Genes & Development. PMID 29567766 DOI: 10.1101/gad.305854.117 |
0.318 |
|
| 2012 |
Bonet C, Giuliano S, Ohanna M, Bille K, Allegra M, Lacour JP, Bahadoran P, Rocchi S, Ballotti R, Bertolotto C. Aurora B is regulated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells. The Journal of Biological Chemistry. 287: 29887-98. PMID 22767597 DOI: 10.1074/jbc.M112.371682 |
0.389 |
|
| 2010 |
Fenouille N, Puissant A, Dufies M, Robert G, Jacquel A, Ohanna M, Deckert M, Pasquet JM, Mahon FX, Cassuto JP, Raynaud S, Tartare-Deckert S, Auberger P. Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC. Cancer Research. 70: 9659-70. PMID 21098700 DOI: 10.1158/0008-5472.CAN-10-2034 |
0.441 |
|
| 2010 |
Giuliano S, Cheli Y, Ohanna M, Bonet C, Beuret L, Bille K, Loubat A, Hofman V, Hofman P, Ponzio G, Bahadoran P, Ballotti R, Bertolotto C. Microphthalmia-associated transcription factor controls the DNA damage response and a lineage-specific senescence program in melanomas. Cancer Research. 70: 3813-22. PMID 20388797 DOI: 10.1158/0008-5472.CAN-09-2913 |
0.37 |
|
| 2010 |
Cheli Y, Ohanna M, Ballotti R, Bertolotto C. Fifteen-year quest for microphthalmia-associated transcription factor target genes. Pigment Cell & Melanoma Research. 23: 27-40. PMID 19995375 DOI: 10.1111/j.1755-148X.2009.00653.x |
0.308 |
|
| 2006 |
Sotiropoulos A, Ohanna M, Kedzia C, Menon RK, Kopchick JJ, Kelly PA, Pende M. Growth hormone promotes skeletal muscle cell fusion independent of insulin-like growth factor 1 up-regulation. Proceedings of the National Academy of Sciences of the United States of America. 103: 7315-20. PMID 16670201 DOI: 10.1073/Pnas.0510033103 |
0.7 |
|
| 2005 |
Ohanna M, Sobering AK, Lapointe T, Lorenzo L, Praud C, Petroulakis E, Sonenberg N, Kelly PA, Sotiropoulos A, Pende M. Atrophy of S6K1(-/-) skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control. Nature Cell Biology. 7: 286-94. PMID 15723049 DOI: 10.1038/Ncb1231 |
0.799 |
|
| Show low-probability matches. |